Epic Sciences has secured $52m in a series E funding round, led by private equity firm Blue Ox Healthcare Partners, to develop its cancer diagnostic tests. The company said it had raised the funds from investors including existing and new investors, as well as new investors.
Epic Sciences has secured $52m in a series E funding round, led by private equity firm Blue Ox Healthcare Partners, to develop its cancer diagnostic tests. The US company will use the funding to create further blood tests, known as liquid biopsies, which help determine the best course of treatment for patients with cancer.